{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:25:23Z","timestamp":1791519923207,"version":"4.3.4"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with hypertension are at a high risk of atrial fibrillation (AF). Recent research has indicated the varying effects of antihypertensive medications on developing AF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We investigated the relationship between different types of antihypertensive medications and the risk of AF occurrence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed data from 113,582 subjects with national health screening examinations between 2009 and 2014. The study population was categorized according to antihypertensive medication type. The primary outcome was the incidence of AF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 113,582 subjects (mean age 59.4\u2009\u00b1\u200912.0 years, 46.7% men), 93,557 received monotherapy [angiotensin receptor blockers (ARB), angiotensin-converting enzyme inhibitors (ACEi), beta-blockers, calcium channel blockers (CCB), or diuretics], while 34,590 received combination therapy (ARB\/beta-blockers, ARB\/CCB, ARB\/diuretics, or ARB\/CCB\/diuretics). During a mean follow-up duration of 7.6\u2009\u00b1\u20092.1 years, 3.9% of patients were newly diagnosed with AF. In monotherapy, ACEi and CCB had similar AF risks as ARB, while beta-blockers and diuretics showed higher AF risks than ARB. In combination therapy, ARBs\/CCBs and ARBs\/diuretics had the lowest AF risk, whereas ARBs\/beta-blockers had the highest compared to ARB\/CCB. Among the specific ARBs, the AF risk varied insignificantly, except for telmisartan and candesartan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In hypertensive patients receiving monotherapy, ACEi and CCB showed a similar AF risk as ARBs, while beta-blockers and diuretics were associated with a higher risk. Among those receiving combination therapy, ARBs\/CCBs and ARBs\/diuretics had the lowest AF risk, whereas ARBs\/beta-blockers showed the highest risk. Various types of ARBs have different associations with AF risk.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1372505","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T04:32:03Z","timestamp":1715229123000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Association between types of antihypertensive medication and the risk of atrial fibrillation: a nationwide population study"],"prefix":"10.3389","volume":"11","author":[{"given":"JungMin","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Ryoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eue-Keun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Jeong","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soonil","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongseong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Do","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seil","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/s0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","article-title":"Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension","volume":"18","author":"Zhou","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/s0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7326\/0003-4819-55-1-33","article-title":"Factors of risk in the development of coronary heart disease\u2013six year follow-up experience. The framingham study","volume":"55","author":"Kannel","year":"1961","journal-title":"Ann Intern Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/s0140-6736(18)32225-6","article-title":"Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/s0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e65174","DOI":"10.1371\/journal.pone.0065174","article-title":"The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis","volume":"8","author":"Singh","year":"2013","journal-title":"PLoS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/europace\/eux091","article-title":"Hypertension and cardiac arrhythmias: a consensus document from the European heart rhythm association (EHRA) and ESC council on hypertension, endorsed by the heart rhythm society (HRS), Asia-Pacific heart rhythm society (APHRS) and sociedad latinoamericana de estimulaci\u00f3n card\u00edaca y electrofisiolog\u00eda (SOLEACE)","volume":"19","author":"Lip","year":"2017","journal-title":"Europace"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/circulationaha.110.009035","article-title":"Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the atherosclerosis risk in communities (ARIC) study","volume":"123","author":"Huxley","year":"2011","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.ijcard.2012.12.093","article-title":"Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century","volume":"167","author":"Ball","year":"2013","journal-title":"Int J Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3390\/medicina58111513","article-title":"Incidence and determinants of spontaneous cardioversion of early onset symptomatic atrial fibrillation","volume":"58","author":"Mariani","year":"2022","journal-title":"Medicina"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jacc.2018.05.076","article-title":"Ideal blood pressure in patients with atrial fibrillation","volume":"72","author":"Kim","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/hjh.0000000000002346","article-title":"Atrial fibrillation and the risk of cardiovascular disease and mortality in the hypertension in the very elderly trial","volume":"38","author":"Antikainen","year":"2020","journal-title":"J Hypertens"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/j.jacc.2010.01.043","article-title":"Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis","volume":"55","author":"Schneider","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/eurheartj\/eht507","article-title":"Antihypertensive treatment and risk of atrial fibrillation: a nationwide study","volume":"35","author":"Marott","year":"2013","journal-title":"Eur Heart J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7326\/0003-4819-152-2-201001190-00005","article-title":"Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study","volume":"152","author":"Schaer","year":"2010","journal-title":"Ann Intern Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/s0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ahj.2005.06.036","article-title":"Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program","volume":"152","author":"Ducharme","year":"2006","journal-title":"Am Heart J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","article-title":"Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for end point reduction in hypertension (LIFE) study","volume":"45","author":"Wachtell","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1161\/01.Cir.0000072793.81076.D4","article-title":"Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/ije\/dyw253","article-title":"Data resource profile: the national health information database of the national health insurance service in South Korea","volume":"46","author":"Cheol Seong","year":"2017","journal-title":"Int J Epidemiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"754","DOI":"10.4070\/kcj.2020.0171","article-title":"Cardiovascular research using the Korean national health information database","volume":"50","author":"Choi","year":"2020","journal-title":"Korean Circ J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.hrthm.2019.07.006","article-title":"Effect of the variability of blood pressure, glucose level, total cholesterol level, and body mass index on the risk of atrial fibrillation in a healthy population","volume":"17","author":"Lee","year":"2020","journal-title":"Heart Rhythm"},{"key":"B25","doi-asserted-by":"publisher","first-page":"19224","DOI":"10.1038\/s41598-020-75822-y","article-title":"Association between clustering of unhealthy lifestyle factors and risk of new-onset atrial fibrillation: a nationwide population-based study","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.1038\/s41598-021-84307-5","article-title":"Lifestyle is associated with atrial fibrillation development in patients with type 2 diabetes mellitus","volume":"11","author":"Park","year":"2021","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ahj.2004.09.033","article-title":"Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the valsartan heart failure trial (Val-HeFT)","volume":"149","author":"Maggioni","year":"2005","journal-title":"Am Heart J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/s0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/s0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.jacc.2004.11.070","article-title":"Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis","volume":"45","author":"Healey","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1161\/01.cir.101.22.2612","article-title":"Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation","volume":"101","author":"Nakashima","year":"2000","journal-title":"Circulation"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/s0735-1097(03)00464-9","article-title":"Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation","volume":"41","author":"Kumagai","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1048077","DOI":"10.3389\/fcvm.2022.1048077","article-title":"Effect of angiotensin receptor-neprilysin inhibitor on atrial electrical instability in atrial fibrillation","volume":"9","author":"Zhu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/hyp.0000000000000065","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"B35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1055\/s-0041-1739411","article-title":"2021 focused update consensus guidelines of the Asia pacific heart rhythm society on stroke prevention in atrial fibrillation: executive summary","volume":"122","author":"Chao","year":"2022","journal-title":"Thromb Haemost"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1055\/s-0043-1769612","article-title":"Mobile health-technology-integrated care for atrial fibrillation: a win ratio analysis from the mAFA-II randomized clinical trial","volume":"123","author":"Romiti","year":"2023","journal-title":"Thromb Haemost"},{"key":"B38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1055\/a-1515-9630","article-title":"Adherence to the \u201catrial fibrillation better care\u201d pathway in patients with atrial fibrillation: impact on clinical outcomes-A systematic review and meta-analysis of 285,000 patients","volume":"122","author":"Romiti","year":"2022","journal-title":"Thromb Haemost"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e005163","DOI":"10.1161\/jaha.116.005163","article-title":"Beta-blocker use is associated with impaired left atrial function in hypertension","volume":"6","author":"Sardana","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"B40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1161\/circimaging.108.793190","article-title":"Impact of mild hypertension on left atrial size and function","volume":"2","author":"Eshoo","year":"2009","journal-title":"Circ Cardiovasc Imaging"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.hrthm.2010.05.010","article-title":"Hypertension and atrial fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model","volume":"7","author":"Lau","year":"2010","journal-title":"Heart Rhythm"},{"key":"B42","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/europace\/euv366","article-title":"Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis","volume":"18","author":"Liu","year":"2016","journal-title":"Europace"},{"key":"B43","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1124\/pr.112.007278","article-title":"A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists","volume":"65","author":"Michel","year":"2013","journal-title":"Pharmacol Rev"},{"key":"B45","first-page":"26f","article-title":"Pharmacological properties of angiotensin II receptor antagonists","author":"Timmermans","year":"1999","journal-title":"Can J Cardiol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1124\/jpet.113.211722","article-title":"Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor \u03b3 among clinically used angiotensin II receptor blockers: drug-target interaction analyses","volume":"349","author":"Kakuta","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1248\/bpb.b15-00577","article-title":"Effects of angiotensin II receptor blockers on metabolism of arachidonic acid via CYP2C8","volume":"38","author":"Senda","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"B48","doi-asserted-by":"publisher","first-page":"18s","DOI":"10.1016\/s0895-7061(99)00250-2","article-title":"Newly emerging pharmacologic differences in angiotensin II receptor blockers","volume":"13","author":"Oparil","year":"2000","journal-title":"Am J Hypertens"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1093\/eurheartj\/ehx316","article-title":"Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea","volume":"38","author":"Lee","year":"2017","journal-title":"Eur Heart J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10654-022-00914-0","article-title":"Blood pressure, hypertension and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies","volume":"38","author":"Aune","year":"2023","journal-title":"Eur J Epidemiol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1372505\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T04:32:08Z","timestamp":1715229128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1372505\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":50,"alternative-id":["10.3389\/fcvm.2024.1372505"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1372505","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"article-number":"1372505"}}